MedPath

Catherine Bollard

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Haploidentical Hematopoietic Stem Cell Transplantation

Phase 1
Completed
Conditions
Thalassemia
Sickle Cell-thalassemia Disease
Interventions
Drug: peripheral blood stem cell graft that are CD34+ selected
First Posted Date
2014-06-17
Last Posted Date
2024-12-19
Lead Sponsor
Catherine Bollard
Target Recruit Count
7
Registration Number
NCT02165007
Locations
🇺🇸

Childrens National Medical Center, Washington, District of Columbia, United States

Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease

Phase 1
Completed
Conditions
Inflammatory Bowel Diseases
Interventions
Biological: Allogeneic bone marrow-derived mesenchymal stromal cells
First Posted Date
2014-05-30
Last Posted Date
2024-05-06
Lead Sponsor
Catherine Bollard
Target Recruit Count
1
Registration Number
NCT02150551
Locations
🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma

Phase 1
Completed
Conditions
Severe Chronic Active EBV Infection Syndrome (SCAEBV)
Hodgkin Disease
Non Hodgkin Lymphoma
Lymphoepithelioma
Leiomyosarcoma
Interventions
Drug: LMP1/2 CTLs (Group A)
Drug: LMP1/2 CTLs (Group B)
First Posted Date
2013-10-08
Last Posted Date
2024-12-19
Lead Sponsor
Catherine Bollard
Target Recruit Count
10
Registration Number
NCT01956084
Locations
🇺🇸

Childrens National Medical Center, Washington, District of Columbia, United States

Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)

Phase 1
Active, not recruiting
Conditions
EBV
CMV
Adenovirus
Interventions
Drug: CTL for CMV seropositive donors
Drug: CTL for CMV naïve donors
First Posted Date
2013-09-19
Last Posted Date
2024-08-28
Lead Sponsor
Catherine Bollard
Target Recruit Count
27
Registration Number
NCT01945814
Locations
🇺🇸

Childrens National Medical Center, Washington, District of Columbia, United States

© Copyright 2025. All Rights Reserved by MedPath